Sun Pharma Bolsters Specialty Portfolio with Checkpoint Acquisition

Sun Pharma has bought US immunotherapy and targeted oncology firm Checkpoint Therapeutics for $355 million. The transaction brings UNLOXCYT, an FDA-approved drug for advanced cutaneous squamous cell carcinoma, to Sun Pharma's portfolio. The acquisition expands Sun Pharma's international onco-derm franchise, using its international footprint to drive patient access to UNLOXCYT. Checkpoint stockholders will be paid $4.10 per share with possible additional consideration tied to European approvals. The deal is set to close during Q2 2025, pending regulatory and shareholder approvals.

 

Source: Times of India, Pharmaceutical Technology, Business Standard, Reuters